---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-051345"
form_type: "8-K"
ticker: "LXEO"
cik: "0001907108"
company_name: "Lexeo Therapeutics, Inc."
filed_at: "2025-04-07T23:59:59+00:00"
generated_at: "2026-05-23T20:16:32.091545+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Lexeo reports positive interim Phase 1/2 data for LX2006 in FA cardiomyopathy; 25% LVMI reduction

## Summary
- Participants with abnormal LVMI at baseline achieved 25% mean reduction by 12 months or sooner.
- High-dose cohort (Cohort 3) showed 115% mean increase in cardiac frataxin expression at 3 months.
- LX2006 well tolerated; no Grade 3+ SAEs, no complement activation, no discontinuations.
- FDA alignment on co-primary endpoints (LVMI >10% improvement, any frataxin increase) for registrational study.
- Registrational study expected to initiate by early 2026; natural history study enrollment starts Q2 2025.

## SEC filing metadata
- accession: 0000950170-25-051345
- form_type: 8-K
- ticker: LXEO
- cik: 0001907108
- company_name: Lexeo Therapeutics, Inc.
- filed_at: 2025-04-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/0000950170-25-051345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/lxeo-20250407.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-051345
- JSON: https://secwatch.observer/filing/0000950170-25-051345.json
- Plain text: https://secwatch.observer/filing/0000950170-25-051345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.